28-Mar-2024
No headlines found.
Globe Newswire (Fri, 8-Mar 9:33 AM ET)
DBV Technologies Reports Full Year 2023 Financial Results and Business Update
Globe Newswire (Thu, 7-Mar 4:30 PM ET)
DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024
Globe Newswire (Mon, 4-Mar 4:30 PM ET)
DBV Technologies to Participate in Upcoming AAAAI 2024 Congress
Globe Newswire (Tue, 20-Feb 4:30 PM ET)
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
Globe Newswire (Tue, 16-Jan 4:30 PM ET)
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.
DBV Technologies S.A. - American Depositary Shares trades on the NASDAQ stock market under the symbol DBVT.
As of March 28, 2024, DBVT stock price declined to $0.75 with 14,556 million shares trading.
DBVT has a beta of 0.31, meaning it tends to be less sensitive to market movements. DBVT has a correlation of 0.01 to the broad based SPY ETF.
DBVT has a market cap of $144.11 million. This is considered a Micro Cap stock.
Last quarter DBV Technologies S.A. - American Depositary Shares reported $9 million in Revenue and -$.06 earnings per share. This beat revenue expectation by $8 million and exceeded earnings estimates by $.19.
In the last 3 years, DBVT stock traded as high as $6.88 and as low as $.65.
The top ETF exchange traded funds that DBVT belongs to (by Net Assets): APIE.
DBVT has underperformed the market in the last year with a price return of -54.0% while the SPY ETF gained +33.6%. DBVT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -28.0% and -9.9%, respectively, while the SPY returned +10.1% and +1.7%, respectively.
DBVT support price is $.73 and resistance is $.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DBVT stock will trade within this expected range on the day.